HIV anti-retroviral treatment -discrepancy in treatment means twice survival rate

New study measures HIV anti-retroviral regimens' safety and efficacy: "A study in the New England Journal of Medicine released on World AIDS Day reports that viral failure, the point at which medication can no longer suppress the HIV infection, was twice as likely and happened sooner among patients initiating anti-retroviral therapy with high viral loads who were given Epzicom when compared to similar patients treated with Truvada."